RxDoctor Payments Data

Lemolls Johny

Family · Rockville, MDNPI 1467639971

Payments from drug & device makers

$718in general payments, 2019–2025

Across 8 payments — averaging $89.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$123
  • AbbVie$111
  • Amgen$110
  • Dynavax Technologies Corporation$109
  • Grifols USA, LLC$103
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$91
  • plus $71 from 2 others

What the payments were for

  • Food & beverage$718100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$718 in reported general payments places this provider in the 65th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$122,966
Medicare patients
560
Services billed
1,463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban30$27,049
MounjaroTirzepatide20$17,037
JardianceEmpagliflozin11$12,171
MyrbetriqMirabegron13$5,612
Atorvastatin Calcium217$2,766
SynthroidLevothyroxine Sodium22$1,859
Ezetimibe39$1,707
Losartan Potassium132$1,495
Levothyroxine Sodium116$1,428
Bupropion XlBupropion Hcl32$1,161
Omeprazole67$1,056
Metoprolol Succinate60$1,039
Albuterol Sulfate HfaAlbuterol Sulfate46$852
Amlodipine Besylate110$799
Rosuvastatin Calcium39$706

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$111$1,85922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,843 family providers in Maryland.

Other family in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →